ArticleApplied biochemistry and biotechnology2026
METTL3-Modified FOXM1 Promotes Proliferation, Invasion, Stemness, and Immune Escape of Gastric Cancer by Influencing the Transcription of FGFR4.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Forkhead box M1 (FOXM1) has been identified as a key gene regulating immune escape in gastric cancer (GC). Therefore, elucidation of FOXM1-related molecular mechanisms may provide more information for immunotherapy of GC. Methods: The expression levels of FOXM1, methyltransferase like 3 (METTL3), and fibroblast growth factor receptor 4 (FGFR4) were analyzed using qRT-PCR and western blot. EdU assay, flow cytometry, transwell assay and sphere formation assay were used to assess cell proliferation, apoptosis, invasion and stemness. GC cells were co-cultured with phytohemagglutinin-stimulated PBMCs to measure the levels of immune-related factors by ELISA. CD8 + T cell apoptosis rate was analyzed by flow cytometry after co-cultured with GC cells. The interaction between FOXM1 and FGFR4/METTL3/IGF2BP2 was confirmed using ChIP assay, dual-luciferase reporter assay, MeRIP assay, RNA pull-down assay and RIP assay. Animal study was performed to explore the role of METTL3/FOXM1 in vivo. Results: FOXM1 expression was elevated in GC cells. FOXM1 knockdown promoted GC cell apoptosis and the levels of immune-related factors, while inhibiting cell proliferation, invasion, stemness and CD8 + T-cell apoptosis. FOXM1 bound to FGFR4 promoter to increase its transcription. FGFR4 overexpression reversed the promoting effect of FOXM1 knockdown on GC cell proliferation, invasion, stemness and immune escape. METTL3 could promote FOXM1 mRNA stability and expression by m6A modification, which was recognized by m6A reader IGF2BP2. METTL3 silencing suppressed GC cell proliferation, invasion, stemness and immune escape, while these effects were abolished by FOXM1 upregulation. In addition, interference of METTL3 reduced GC tumorigenesis by inhibiting FOXM1/FGFR4 axis. Conclusion: METTL3/FOXM1/FGFR4 is a key regulatory axis in regulating GC progression and immune escape, which may provide potential molecular targets for immunotherapy of GC.
Indexed as
Identifiers
41879922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.